pharmaphorum

SEPTEMBER 15, 2022

The competition authorities in Switzerland said this morning they have carried out a raid on a pharma company – now confirmed to be Novartis – as part of an investigation into a “possible unlawful use of a patent to reduce competitive pressure.”

Dermatology 118

Dermatology Production Pharma Companies Marketing 118

XTalks

NOVEMBER 2, 2023

The biosimilar to Johnson & Johnson’s Stelara is approved for use by adults for the listed indications, as well as pediatric patients six years of age and older for the dermatologic indications (plaque psoriasis and psoriatic arthritis). Amjevita is the first biosimilar of AbbVie’s blockbuster autoimmune drug Humira to enter the market.

FDA Approval 59

FDA Approval Production Dermatology Sales 59

Pharma Marketing Network

APRIL 4, 2022

The American Academy of Dermatology (AAD) held its annual conference last weekend, and it was my privilege to be in attendance. As COVID-19 had put the brakes on the show for the past two years, that same sentiment was shared by most of the attendees and exhibitors this year.

Dermatology 52

Dermatology Cosmetics Pharma Companies Branding 52

Pharma Marketing Network

MARCH 3, 2025

Introduction Pharma marketing has evolved. But how can pharma brands optimize their digital assets while staying compliant with industry regulations? By refining user experience, messaging, and engagement strategies, pharma companies can increase prescription intent, patient adherence, and HCP interaction rates.

Branding 52

Branding Compliance Marketing Dermatology 52

pharmaphorum

JULY 8, 2022

Pharma companies have begun to explore a host of novel digital endpoints that could have far-reaching implications for accelerating drug development and adoption. Reites comments that “our partnership strategy is to align with companies that have an equal view of the market. Novel digital endpoints. About the author.

Clinical Trials 100

Clinical Trials Clinical Trials Trials Regulation 100

pharmaphorum

JUNE 2, 2021

The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa’s home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus royalties on sales. Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

pharmaphorum

JULY 9, 2021

There’s an enormous market for similar approaches in other disease areas. “In The company has also expanded the platform into similar inflammatory conditions in rheumatology, dermatology and oncology. In an ideal world, we’d like every patient to have their own pain specialist, psychologist, dietitian, etc.,

Doctors 69

Doctors Doctor Marketing Development 69